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OLIVE Registry, a Prospective Multicenter
Study of Patients with Critical Limb IschemiaWe would like to thank Dr. Philip for his interest in
the OLIVE (A Prospective, Multi-Center, Three-Year
Follow-Up Study on Endovascular Treatment for
Infra-Inguinal Vessel in Patients With Critical Limb
Ischemia) registry (1) evaluating outcomes of endo-
vascular treatment for infrainguinal vessels in pa-
tients with critical limb ischemia (CLI). One issue that
was pointed out this time described problems in
the current treatments for patients with CLI. We
completely agree with Dr. Philip that the quality of
baseline medical therapy is extremely important
when assessing and comparing the overall quality
and cost of vascular care. As noted, we have
no evidence that the medical costs associated
with revascularization with endovascular therapy
actually prevent amputation, whereas the efﬁcacy of
optimal medical therapy (OMT) for amputation
prevention and prognosis improvement has not
been established, either (2). The current guidelinesrecommend OMT for peripheral arterial disease
(PAD) as follows: 1) antiplatelet therapy; 2) statins;
and 3) angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers. There is a report that
the administration of 2 or more of these agents re-
duces mortality. However, we should also note the
lack of consistency in the provision and adherence
of these recommended therapies in PAD patients (3).
Some antiplatelet drugs and statins have been
reported to improve limb prognosis (2). The OLIVE
study demonstrated a low administration rate of sta-
tins in the real world. In this study, 52% of subjects
were on dialysis, 41% had hyperlipidemia, and the
mean body mass index was 22, but the administration
rate of statins was as low as 26%. Inadequate drug
treatment for PAD and poor adherence of patients
have recently been reported (4,5), and it is meaning-
ful that the OLIVE study also revealed that OMT is
rarely provided for CLI in actual clinical practice.
Among CLI patients in the clinical setting, some pre-
sented with hypotension or terminal status of arte-
riosclerosis with sarcopenia. For these patients facing
such a prognosis, both OMT administration and
revascularization are controversial. Either way, the
evidence level for the role of OMT for CLI is insufﬁ-
cient, and such veriﬁcation is urgently necessary.
The onset and progression of CLI are strongly
correlated with diabetes mellitus and renal failure.
Patients with these complications present with a
higher prevalence of infrainguinal arterial lesions,
which have a high rate of restenosis and reinterven-
tion after endovascular therapy. In the OLIVE study,
the percentage of subjects with diabetes mellitus and
those on dialysis was as high as 71% and 52%,
respectively, and approximately 75% had the infra-
popliteal arterial lesions, resulting in high rates of
restenosis and reintervention (1). In patients with rest
pain or ulcers/gangrene who developed a ﬁrst episode
or recurrence, reintervention seemed to be both
inevitable and the only option: the medical inter-
vention to prevent major amputations provides only
class III guidance in the current guideline. On the
other hand, repeated revascularization is an addi-
tional ﬁnancial burden, despite providing only local
treatment. A general treatment model, including
systemic treatment and social aspects, should be
considered in order to improve CLI prognosis as
well as medical cost burdens. Even if revasculariza-
tion is the ﬁrst-line treatment for CLI, this does not
necessarily justify repeated interventions performed
within a short period of time.Osamu Iida, MD
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